Radient Pharmaceuticals Corp (RPC) announced today Mathi Senapathi has joined the company’s executive management team as Director of Manufacturing, responsible for the manufacturing of RPC’s Onko-Sure® in vitro diagnostic (IVD) cancer test kits.

Senapathi has over 18 years of diverse pharmaceutical industry experience, including roles in laboratory quality control and research, quality assurance, advanced clinical and anatomic pathology, regulatory compliance and systems monitoring and control for GLP, GMP and GCP; and program monitoring for ISO9001, ISO 13485.2003 drug safety evaluation.

"Mathi is a strong addition to RPC’s management team and his appointment speaks volumes to RPC’s investment in the continued commercialization for Onko-Sure," said Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals. "We continue to advance our manufacturing operation in support of our domestic and international sales pipeline. Mathi will be a major contributor to current and future manufacturing efforts and I am pleased to welcome him to the team."

Most recently Senapathi worked as Director of Quality Assurance at Pathogenesys. In this position, Senapathi’s scope of responsibility included establishing and overseeing quality systems and compliance programs as they related to GLP and ISO9001, ISO 13485.2003. He also held the role of FDA and research compliance audit liaison. Prior to this  Senapathi was employed with Allergen and Meyer Pharmaceuticals where he held various progressively responsible roles in manufacturing; risk management; regulatory and SOP training; assay development, validation and data collection and maintenance; and clinical trials.

Senapathi holds a Master’s Degree in Philosophy; Master’s Degree in Arts; and a Bachelor of Science Degree in Biology and Chemistry each from Madras University, India. In addition, he has extensive training in Risk Management Systems and Medical Devices from Virginia Polytechnic and State University.

Source: Radient Pharmaceuticals Corp